These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 33138142)

  • 1. Why the Anti-Meningococcal B Vaccination during Adolescence Should Be Implemented in Italy: An Overview of Available Evidence.
    Boccalini S; Zanella B; Landa P; Amicizia D; Bechini A; Innocenti M; Iovine M; Lecini E; Marchini F; Paolini D; Sartor G; Zangrillo F; Lai PL; Bonanni P; Panatto D
    Microorganisms; 2020 Oct; 8(11):. PubMed ID: 33138142
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Persistence and 4-year boosting of the bactericidal response elicited by two- and three-dose schedules of MenB-FHbp: A phase 3 extension study in adolescents.
    Vesikari T; Østergaard L; Beeslaar J; Absalon J; Eiden JJ; Jansen KU; Jones TR; Harris SL; Maansson R; Munson S; O'Neill RE; York LJ; Perez JL
    Vaccine; 2019 Mar; 37(12):1710-1719. PubMed ID: 30770221
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Protecting UK adolescents and adults against meningococcal serogroup B disease.
    Vyse A; Ellsbury G; Madhava H
    Expert Rev Vaccines; 2018 Mar; 17(3):229-237. PubMed ID: 29374982
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Parental awareness and utilization of meningococcal serogroup B vaccines in the United States.
    Srivastava A; Dempsey A; Galitsky A; Fahimi M; Huang L
    BMC Public Health; 2020 Jul; 20(1):1109. PubMed ID: 32664872
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epidemiology of invasive meningococcal B disease in Australia, 1999-2015: priority populations for vaccination.
    Archer BN; Chiu CK; Jayasinghe SH; Richmond PC; McVernon J; Lahra MM; Andrews RM; McIntyre PB;
    Med J Aust; 2017 Nov; 207(9):382-387. PubMed ID: 29092704
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The cost-of-illness for invasive meningococcal disease caused by serogroup B Neisseria meningitidis (MenB) in Germany.
    Scholz S; Koerber F; Meszaros K; Fassbender RM; Ultsch B; Welte RR; Greiner W
    Vaccine; 2019 Mar; 37(12):1692-1701. PubMed ID: 30661834
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost of Illness Analysis of Invasive Meningococcal Disease Caused by Neisseria Meningitidis Serogroup B in the Netherlands-a Holistic Approach.
    Zeevat F; Simons JJM; Westra TA; Wilschut JC; van Sorge NM; Boersma C; Postma MJ
    Infect Dis Ther; 2024 Mar; 13(3):481-499. PubMed ID: 38366286
    [TBL] [Abstract][Full Text] [Related]  

  • 8. First statewide meningococcal B vaccine program in infants, children and adolescents: evidence for implementation in South Australia.
    Marshall HS; Lally N; Flood L; Phillips P
    Med J Aust; 2020 Feb; 212(2):89-93. PubMed ID: 31909501
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multicomponent meningococcal B vaccination (4CMenB) of adolescents and college students in the United States.
    Banzhoff A
    Ther Adv Vaccines; 2017 Feb; 5(1):3-14. PubMed ID: 28344804
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Health and economic outcomes of introducing the new MenB vaccine (Bexsero) into the Italian routine infant immunisation programme.
    Tirani M; Meregaglia M; Melegaro A
    PLoS One; 2015; 10(4):e0123383. PubMed ID: 25874805
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Introduction of a second MenB vaccine into Europe - needs and opportunities for public health.
    Findlow J; Nuttens C; Kriz P
    Expert Rev Vaccines; 2019 Mar; 18(3):225-239. PubMed ID: 30821535
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Economic evaluation of meningococcal serogroup B childhood vaccination in Ontario, Canada.
    Tu HA; Deeks SL; Morris SK; Strifler L; Crowcroft N; Jamieson FB; Kwong JC; Coyte PC; Krahn M; Sander B
    Vaccine; 2014 Sep; 32(42):5436-46. PubMed ID: 25131732
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Meningococcal B vaccine (4CMenB): the journey from research to real world experience.
    Rappuoli R; Pizza M; Masignani V; Vadivelu K
    Expert Rev Vaccines; 2018 Dec; 17(12):1111-1121. PubMed ID: 30457407
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Parental awareness of Meningococcal B vaccines and willingness to vaccinate their teens.
    Basta NE; Becker AB; Li Q; Nederhoff D
    Vaccine; 2019 Jan; 37(4):670-676. PubMed ID: 30587431
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical data supporting a 2-dose schedule of MenB-FHbp, a bivalent meningococcal serogroup B vaccine, in adolescents and young adults.
    Beeslaar J; Absalon J; Balmer P; Srivastava A; Maansson R; York LJ; Perez JL
    Vaccine; 2018 Jun; 36(28):4004-4013. PubMed ID: 29861182
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lessons from mass vaccination response to meningococcal B outbreaks at US universities.
    Alderfer J; Isturiz RE; Srivastava A
    Postgrad Med; 2020 Sep; 132(7):614-623. PubMed ID: 32476532
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Invasive meningococcal disease in England and Wales: implications for the introduction of new vaccines.
    Ladhani SN; Flood JS; Ramsay ME; Campbell H; Gray SJ; Kaczmarski EB; Mallard RH; Guiver M; Newbold LS; Borrow R
    Vaccine; 2012 May; 30(24):3710-6. PubMed ID: 22429756
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Background Paper for the update of meningococcal vaccination recommendations in Germany: use of the serogroup B vaccine in persons at increased risk for meningococcal disease.
    Hellenbrand W; Koch J; Harder T; Bogdan C; Heininger U; Tenenbaum T; Terhardt M; Vogel U; Wichmann O; von Kries R
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2015 Nov; 58(11-12):1314-43. PubMed ID: 26487381
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Meningococcal serogroup B vaccine in Italy: state-of-art, organizational aspects and perspectives.
    Signorelli C; Chiesa V; Odone A
    J Prev Med Hyg; 2015 Aug; 56(3):E125-32. PubMed ID: 26788733
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Distribution of invasive meningococcal B disease in Italian pediatric population: implications for vaccination timing.
    Azzari C; Canessa C; Lippi F; Moriondo M; Indolfi G; Nieddu F; Martini M; de Martino M; Castiglia P; Baldo V; Resti M;
    Vaccine; 2014 Feb; 32(10):1187-91. PubMed ID: 24120548
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.